(Q36839739)

16 August 2017

1 reference

title

Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches (English)

1 reference

16 August 2017

1 reference

1 reference

Aharona Glatman-Freedman

series ordinal

3

object named as

Aharona Glatman-Freedman

1 reference

16 August 2017

2

Arturo Casadevall

1 reference

16 August 2017

1

Jacqueline M Achkar

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Anti-infective Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

461-474

1 reference

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

The success and failure of BCG - implications for a novel tuberculosis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Pulmonary resection for multi-drug resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Effectiveness of directly observed therapy (DOT) for tuberculosis: a review of multinational experience reported in 1990-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Advances in antibody-mediated immunity againstMycobacterium tuberculosis: implications for a novel vaccine strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Reconsidering adjuvant immunotherapy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Impact of HIV infection on tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Current and future clinical applications of interferon-gamma in host antimicrobial defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Disseminated tuberculosis in interferon gamma gene-disrupted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Multiple defects of immune cell function in mice with disrupted interferon-gamma genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Interferon-gamma in the management of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guérin infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Lack of induction of interleukin-2-receptor-alpha in patients with tuberculosis and human immunodeficiency virus co-infection: implications for pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Interleukin-12 therapy reduces the number of immune cells and pathology in lungs of mice infected with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Anti-cytokine therapeutics and infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

New insights into the immunopathology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Recombinant cytokines for controlling mycobacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Thalidomide for erythema nodosum leprosum and other applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

The damage-response framework of microbial pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.461

21 January 2018

Identifiers

DOI

10.1586/14787210.5.3.461

1 reference

16 August 2017

1 reference